In this animal model of NASH, both simvastatin and atorvastatin treatment significantly reduced PP levels compared to vehicle administration (11.24% reduction, p = 0.006, and 13.85% reduction, p < 0.001, for HFGFD-Sim and HFGFD-Ato, respectively) without changing systemic hemodynamics. The gene discussed is SIM2; the disease is metabolic dysfunction-associated steatohepatitis.